Don't give Tom MS but do send him to Italy for some common sense training?
ffects of Bacille Calmette-Guerin after the first demyelinating event in the CNS.
Ristori
G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P,
Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M,
Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti
M.
Neurology. 2014 Jan 7;82(1):41-8. doi: 10.1212/01.wnl.0000438216.93319.ab. Epub 2013 Dec 4.
- PMID:
- 24306002
- [PubMed - indexed for MEDLINE]
RSSResult Filters
Neurology. 1999 Oct 22;53(7):1588-9.
Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.
Ristori G1, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, Salvetti M.
Abstract
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Comment in
- Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. [Neurology. 2000]
- PMID:
- 10534275
- [PubMed - indexed for MEDLINE]
Study: Asthma has $1.3B impact on New York
ALBANY, N.Y. - (AP) -- Asthma is costing New York's Medicaid system more than half a billion dollars a year, according to a report released Friday that urges the state to do more to help those affected by the respiratory illness.The study by state Comptroller Thomas DiNapoli found that Medicaid costs related to asthma were $532 million in 2013, an increase of more than 26 percent over five years.
When all non-Medicaid hospitalizations and treatment and lost productivity associated with asthma are counted, the overall cost of the illness to New York rises to $1.3 billion a year, according to an estimate from the state's Department of Health.
"For the New Yorkers fighting this chronic disease, a flare-up can mean missing work or school and too many late night emergency room visits," DiNapoli said in a statement accompanying his report. "The state needs to better understand asthma trends and better target publicly funded initiatives, particularly for Hispanic, African-American and the poorest New Yorkers struggling with this disease."
The report found that while the costs of asthma are up, deaths from the disease are down. Asthma deaths have dropped by nearly 23 percent in the past decade, from 330 in 2002 to 255 in 2011.
Asthma affects 1.7 million residents in the state, with the highest prevalence found in Schenectady and the Bronx. Studies have found that low-income and minority residents are more likely to have the disease.
DiNapoli said state health officials have made progress in expanding asthma treatment for children through school-based health centers and home visits. But he recommended the state do more to focus its efforts on the communities where asthma is most common.
To better combat the illness, the state needs to reach out to children with asthma and their parents, who often may not understand the illness or the ways that it can be treated, according to Sally Findley, a professor at Columbia University's Mailman School of Public Health who has studied asthma.
She said efforts to improve air quality will help, too -- even by planting more trees in urban environments.
"When you are effective at doing these things you can reduce hospitalizations," she said. "It saves money in the long run."
Some of the sharp increase in asthma-related Medicaid expenditures can be tied to the higher number of New Yorkers enrolled in the program. Since 2009, Medicaid enrollment in the state has jumped by 20 percent to 5.7 million. But DiNapoli notes that the percentage of Medicaid participants with asthma has grown faster than Medicaid enrollment overall.
>>> Rigshospitalet <news@meltwaterpress.com> 9/3/2012 9:27 AM >>>
Press release |
||
3rd of September 2012 |
||
Tuberculosis vaccine - a new remedy for allergies and asthma in children? M Can a vaccine against tuberculosis help combat asthma and eczema in Danish children early in life? This will now be examined in a comprehensive Danish research study. >From September 2012, thousands of Danish pregnant women will receive an invitation to allow their newborns to take part in a sensational trial. The tuberculosis vaccine was removed from the vaccine program in Denmark during the 1980s, however new research indicates that the vaccine can improve the health of children. Research carried out in developing countries shows that the health of infants who have been given the tuberculosis vaccine (BCG/Calmette) at birth is improved and the babies have a better survival rate than those who have not been given the vaccine. The vaccine also seems to have a preventive effect against asthma and atopic dermatitis. Results are so striking that they cannot be explained by the fact that the children did not catch tuberculosis. Therefore, researchers assess the vaccine to have a general positive effect on the immune system, which means that children are less sick, and have less atopic dermatitis, asthma and allergies. Whether this positive effect also can benefit Danish children will now be examined in a large Danish research project headed by Lone Graff Stensballe, Paediatrician from the Department of Paediatrics and Adolescent Medicine at Rigshospitalet. The research project will run for three years, starting in September 2012, where 4,300 infants and their parents will be followed through interviews, examinations, and, for 300 of the children, blood tests as well. The project will comprise five PhD courses and a research collaboration with obstetricians, paediatricians, midwives, nurses and laboratory technicians from the three hospitals taking part in the project. “We are very excited about this unique opportunity to improve the health of Danish children early in life,” says Lone Graff Stensballe. “Unfortunately, we have seen large increases in admissions, consumption of medicines, asthma, eczema and allergies among Danish children. We hope to curb these increases with the new research project.” The research project will be carried out at Rigshospitalet in collaboration with Hvidovre Hospital, Kolding Sygehus Lillebælt and the new Centre for Vitamins and Vaccines at SSI (Statens Serum Institut). For further information and interviews, please contact: Lone Graff Stensballe Head of Research Paediatrician, Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Denmark Telephone: +45 6022 8092 E-mail: lone.graff.stensballe@rh.regionh.dk |
||
|
||
Rigshospitalet
– a part of Copenhagen University Hospital – is Denmark'sleading
hospital for patients needing highly specialized treatment.
Rigshospitalet serves all of Denmark, Greenland and the Faroe Islands
within almost all specialties and sub-specialties of medicine and
surgery.
|
Afmelding: Ønsker du ikke længere at få tilsendt e-mails fra Rigshospitalet via Meltwater Press, venligst klik: [her]. Afmelding kan tage op til 2 arbejdsdage.
Hvis du ønsker at kontakte Meltwater Press, kan du kontakte Meltwater Press på:
Meltwater Group Christian IX's Gade 10, 2. 1111 København K
No comments:
Post a Comment